# HÃ¥kan Mellstedt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/840263/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 99<br>papers | 3,365<br>citations | 172457<br>29<br>h-index | 155660<br>55<br>g-index |
| 100<br>all docs | 100<br>docs citations | 100<br>times ranked | 4314<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinibâ€resistant ROR1<sup>+</sup> CLL cells. EJHaem, 2021, 2, 498-502. | 1.0 | 3 |
| 2 | Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung. Cell Death and Disease, 2021, 12, 577. | 6.3 | 11 |
| 3 | Temporary cessation of ibrutinib results in reduced grade 3â€4 infections and durable remissionsâ€"Interim analysis of an onâ€offâ€repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia. EJHaem, 2021, 2, 525-529. | 1.0 | 2 |
| 4 | Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules. Handbook of Experimental Pharmacology, 2021, 269, 75-99. | 1.8 | 5 |
| 5 | ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells. Biomedicines, 2020, 8, 170. | 3.2 | 19 |
| 6 | Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. Iranian Journal of Basic Medical Sciences, 2020, 23, 800-809. | 1.0 | 13 |
| 7 | ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells. Blood, 2019, 134, 5312-5312. | 1.4 | 3 |
| 8 | Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells. Blood, 2019, 134, 2565-2565. | 1.4 | 0 |
| 9 | Expression of the Fractalkine Receptor (CX3CR1) Is Significantly Increased in Immune Cells of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma patients with Active Disease. Blood, 2019, 134, 5445-5445. | 1.4 | 0 |
| 10 | Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients. European Journal of Haematology, 2018, 101, 68-77. | 2.2 | 13 |
| 11 | Dual targeting of Bruton tyrosine kinase and <scp>CD</scp>52 induces minimal residual diseaseâ€negativity in the bone marrow of poorâ€prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections â€“ Results from a phase I study. British Journal of Haematology, 2018, 182, 590-594. | 2.5 | 3 |
| 12 | A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. PLoS ONE, 2018, 13, e0198038. | 2.5 | 27 |
| 13 | Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells. PLoS ONE, 2018, 13, e0192839. | 2.5 | 3 |
| 14 | Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatment in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients. Blood, 2018, 132, 4421-4421. | 1.4 | 0 |
| 15 | Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. Tumor Biology, 2017, 39, 101042831769979. | 1.8 | 45 |
| 16 | T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica, 2017, 102, 562-572. | 3.5 | 121 |
| 17 | Phase Iâ€“II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints. Cancer Immunology, Immunotherapy, 2017, 66, 91-102. | 4.2 | 9 |
| 18 | Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. PLoS ONE, 2017, 12, e0169736. | 2.5 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia. Tumor Biology, 2016, 37, 11947-11957. | 1.8 | 24 |
| 20 | Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions. Oncology Letters, 2016, 12, 2782-2788. | 1.8 | 7 |
| 21 | Ibrutinib-A double-edge sword in cancer and autoimmune disorders. Journal of Drug Targeting, 2016, 24, 373-385. | 4.4 | 21 |
| 22 | Dendritic cell regulation of NKâ€cell responses involves lymphotoxinâ€Î±, ILâ€12, and TGFâ€Î². European Journal of Immunology, 2015, 45, 1783-1793. | 2.9 | 34 |
| 23 | The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies. British Journal of Haematology, 2015, 169, 455-458. | 2.5 | 32 |
| 24 | Biosimilars â€“ terms of use. Current Medical Research and Opinion, 2015, 31, 2325-2330. | 1.9 | 12 |
| 25 | First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells. Blood, 2015, 126, 2912-2912. | 1.4 | 2 |
| 26 | In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study. Blood, 2015, 126, 4164-4164. | 1.4 | 3 |
| 27 | Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia. PLoS ONE, 2015, 10, e0142310. | 2.5 | 12 |
| 28 | Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer. Journal of Gynecologic Oncology, 2014, 25, 221. | 2.2 | 29 |
| 29 | The receptor tyrosine kinase ROR1 â€“ An oncofetal antigen for targeted cancer therapy. Seminars in Cancer Biology, 2014, 29, 21-31. | 9.6 | 85 |
| 30 | Therapeutic vaccines for cancer: an overview of clinical trials. Nature Reviews Clinical Oncology, 2014, 11, 509-524. | 27.6 | 636 |
| 31 | Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. International Journal of Oncology, 2014, 45, 1293-1303. | 3.3 | 56 |
| 32 | Vaccination with Dendritic Cells Loaded with Autologous Leukemic Cells in Combination with Low-Dose Lenalidomide Induced Immune Responses in Chronic Lymphocytic Leukemia (CLL) Patients. Blood, 2014, 124, 4685-4685. | 1.4 | 1 |
| 33 | Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. Leukemia and Lymphoma, 2013, 54, 843-850. | 1.3 | 67 |
| 34 | T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile. Cancer Immunology, Immunotherapy, 2013, 62, 51-63. | 4.2 | 16 |
| 35 | Clinical considerations for biosimilar antibodies. European Journal of Cancer, Supplement, 2013, 11, 1-11. | 2.2 | 42 |
| 36 | Apoptosis induction mediated through PI3-kinase/AKT/mTOR pathway using anti-ROR1 monoclonal antibody in chronic lymphocytic leukemia cells.. Journal of Clinical Oncology, 2013, 31, 7087-7087. | 1.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.. Journal of Clinical Oncology, 2013, 31, e22198-e22198. | 1.6 | 0 |
| 38 | Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria. Cancer Immunology, Immunotherapy, 2012, 61, 865-879. | 4.2 | 46 |
| 39 | Effect of ROR1-targeting small molecules on chronic lymphocytic leukemia (CLL) cells.. Journal of Clinical Oncology, 2012, 30, 6557-6557. | 1.6 | 3 |
| 40 | Metabolic intervention targeting 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) using a structure-based design.. Journal of Clinical Oncology, 2012, 30, e13518-e13518. | 1.6 | 0 |
| 41 | Prognostic value of epithelial cell adhesion molecule (EpCAM) in patients with primary epithelial ovarian cancer.. Journal of Clinical Oncology, 2012, 30, e15531-e15531. | 1.6 | 0 |
| 42 | Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience. Lung Cancer, 2011, 73, 11-17. | 2.0 | 55 |
| 43 | Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. British Journal of Haematology, 2010, 151, 327-335. | 2.5 | 67 |
| 44 | Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. International Journal of Cancer, 2008, 123, 1190-1195. | 5.1 | 154 |
| 45 | T Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities.. Blood, 2008, 112, 2071-2071. | 1.4 | 7 |
| 46 | Telomerase (hTERT 611â€“626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Experimental Hematology, 2007, 35, 297-304. | 0.4 | 50 |
| 47 | Analysis of HLA-G gene expression in B-lymphocytes from chronic lymphocytic leukemia patients. Iranian Biomedical Journal, 2007, 11, 125-129. | 0.7 | 5 |
| 48 | T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunology, Immunotherapy, 2006, 55, 210-220. | 4.2 | 50 |
| 49 | Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL). European Journal of Haematology, 2002, 68, 299-306. | 2.2 | 46 |
| 50 | Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern. British Journal of Haematology, 2001, 115, 263-271. | 2.5 | 25 |
| 51 | Increased serum levels of soluble Fas in progressive B-CLL. European Journal of Haematology, 2001, 66, 342-346. | 2.2 | 29 |
| 52 | Autologous T lymphocytes recognize the tumourâ€derived immunoglobulin VHâ€CDR3 region in patients with Bâ€cell chronic lymphocytic leukaemia. British Journal of Haematology, 2000, 111, 230-238. | 2.5 | 0 |
| 53 | Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 2000, 111, 608-617. | 2.5 | 0 |
| 54 | Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 2000, 111, 230-238. | 2.5 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. , 1999, 80, 671-680. | | 43 |
| 56 | bcl-2 rearrangement detected by pulsed-field gel electrophoresis (PFGE) in B-chronic lymphocytic leukemia (CLL) cells. , 1998, 76, 909-912. | | 6 |
| 57 | Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunology, Immunotherapy, 1998, 47, 131-142. | 4.2 | 92 |
| 58 | T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: Clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden. European Journal of Immunology, 1997, 27, 2245-2252. | 2.9 | 60 |
| 59 | B-CLL cells with unusual properties. , 1997, 70, 1-8. | | 20 |
| 60 | Epstein-Barr virus (EBV) gene expression in lymphoid B cells during acute infectious mononucleosis (IM) and clonality of the directly growing cell lines. , 1997, 71, 345-349. | | 10 |
| 61 | Induction of a T- and B-cell response against a unique amino acid sequence of the mouse IgG2A hinge region in a MAb-treated patient. , 1997, 73, 790-794. | | 1 |
| 62 | Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation. British Journal of Haematology, 1996, 92, 71-76. | 2.5 | 28 |
| 63 | Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunology, Immunotherapy, 1996, 42, 81-87. | 4.2 | 59 |
| 64 | Interleukinâ€10 mRNA expression in Bâ€cell chronic lymphocytic leukaemia inversely correlates with progression of disease. British Journal of Haematology, 1996, 92, 393-400. | 2.5 | 37 |
| 65 | Modulation of antiâ€idiotypic immune response by immunization with the autologous Mâ€component protein in multiple myeloma patients. British Journal of Haematology, 1996, 92, 840-846. | 2.5 | 92 |
| 66 | Bcl-2,Bax andp53 expression in B-CLL in relation toin vitro survival and clinical progression. International Journal of Cancer, 1996, 69, 114-119. | 5.1 | 123 |
| 67 | Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia. British Journal of Haematology, 1996, 93, 151-153. | 2.5 | 219 |
| 68 | Bclâ€2, Bax and p53 expression in Bâ€CLL in relation to in vitro survival and clinical progression. International Journal of Cancer, 1996, 69, 114-119. | 5.1 | 2 |
| 69 | Epstein barr virus (EBV)-carrying cells of a chronic lymphocytic leukemia (CLL) subpopulation express EBNA1 and LMPS but not EBNA2in vivo. International Journal of Cancer, 1995, 63, 486-490. | 5.1 | 13 |
| 70 | Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 andÎ±-IFN. Medical Oncology, 1995, 12, 69-77. | 2.5 | 28 |
| 71 | Expression of Adhesion Molecules CD 11/CD 18 (Leu-CAMs, Î²2-Integrins), CD54 (ICAM-1) and CD58 (LFA-3) in B -Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 1994, 13, 297-306. | 1.3 | 18 |
| 72 | Progressive B-cell chronic lymphocytic leukaemia frequently exhibits aberrantp53 expression. International Journal of Cancer, 1994, 58, 474-479. | 5.1 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Effect of monoclonal antibody 17-1A and gm-CSF in patients with advanced colorectal carcinomaâ€"long-lasting, complete remissions can be induced. International Journal of Cancer, 1993, 53, 751-758. | 5.1 | 94 |
| 74 | Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17â€"1A develop a cellular response (DTH) to the â€œinternal image of the antigenâ€•(ab2). International Journal of Cancer, 1991, 48, 344-349. | 5.1 | 33 |
| 75 | Clonality and methylation status of the epsteinâ€barr virus (EBV) genomes in IN V7Wâ€infected EBVâ€carrying chronic lymphocytic leukemia (CLL) cell lines. International Journal of Cancer, 1991, 48, 62-66. | 5.1 | 15 |
| 76 | Chemotherapy and immunotherapy of colorectal cancer. Medical Oncology and Tumor Pharmacotherapy, 1991, 8, 207-20. | 1.1 | 11 |
| 77 | Oral melphalan pharmacokinetics: Influence of interferon-induced fever. Clinical Pharmacology and Therapeutics, 1990, 47, 86-90. | 4.7 | 18 |
| 78 | Immune deficiency in family members of patients with Hodgkin's disease. Cancer, 1990, 66, 1938-1943. | 4.1 | 16 |
| 79 | Fine-Needle Aspiration Cytology with Immunocytochemistry of Extranodal Manifestations of Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1990, 1, 129-139. | 1.3 | 12 |
| 80 | Clonal cell surface structures related to differentiation, activation and homing in Bâ€cell chronic lymphocytic leukemia and monoclonal lymphocytosis of undetermined significance. European Journal of Haematology, 1989, 43, 452-459. | 2.2 | 30 |
| 81 | Oral melphalan pharmacokinetics â€" relation to dose in patients with multiple myeloma. Medical Oncology and Tumor Pharmacotherapy, 1989, 6, 151-154. | 1.1 | 22 |
| 82 | Treatment of multiple myeloma with natural Î±-interferon. Hematological Oncology, 1988, 6, 187-192. | 1.7 | 9 |
| 83 | Chromosome 13â€¦ new marker for B-cell chronic lymphocytic leukemia. Hereditas, 1988, 108, 77-84. | 1.4 | 28 |
| 84 | Buoyant density characterization of neoplastic cell populations in patients with chronic Bâ€lymphocytic leukemia. European Journal of Haematology, 1988, 40, 142-148. | 2.2 | 2 |
| 85 | Human monoclonal immunoglobulins that bind the human acetylcholine receptor. European Journal of Immunology, 1987, 17, 1867-1869. | 2.9 | 21 |
| 86 | Future Aspects of Cancer Treatment: The Use of Monoclonal Antibodies. International Journal of Technology Assessment in Health Care, 1985, 1, 921-926. | 0.5 | 0 |
| 87 | The large sialoglycoprotein of human lymphocytes. I. Distribution on T and B lineage cells as revealed by a monospecific chicken antibody. European Journal of Immunology, 1985, 15, 417-426. | 2.9 | 24 |
| 88 | Clinical and laboratory findings in untreated patients with Hodgkinâ€™s disease with special reference to age. Medical Oncology and Tumor Pharmacotherapy, 1984, 1, 33-41. | 1.1 | 5 |
| 89 | CORRELATION OF IMMUNOPHENOTYPE TO MORPHOLOGY IN UNFAVOURABLE NONâ€HODGKIN LYMPHOMA. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology, 1983, 91A, 425-433. | 0.3 | 2 |
| 90 | Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-Î±. International Journal of Cancer, 1982, 30, 167-172. | 5.1 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Lymphocytotoxic serum factors and lymphocyte functions in untreated Hodgkin'S disease. Cancer, 1982, 50, 2044-2048. | 4.1 | 13 |
| 92 | Prednimustine and vincristine compared with cytosine arabinoside and thioguanine for treatment of elderly patients with acute nonlymphoblastic leukemia. Cancer Chemotherapy and Pharmacology, 1982, 9, 89-92. | 2.3 | 6 |
| 93 | Longitudinal studies of blood lymphocyte capacity in Hodgkin's disease. Cancer, 1981, 48, 2010-2015. | 4.1 | 31 |
| 94 | Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia. Cancer Chemotherapy and Pharmacology, 1981, 6, 65-73. | 2.3 | 15 |
| 95 | Monoclonal Blood Lymphocytes in Benign Monoclonal Gammopathy and Multiple Myeloma in Relation to Clinical Stage. Scandinavian Journal of Haematology, 1981, 27, 287-293. | 0.0 | 32 |
| 96 | Blood Lymphocyte Functions in Relation to Splenic Weight and Tumor Involvement in Untreated Hodgkin's Disease. Scandinavian Journal of Haematology, 1981, 25, 51-57. | 0.0 | 9 |
| 97 | Longâ€Term Influence of Splenectomy on Immune Functions in Patients with Hodgkin's Disease. Scandinavian Journal of Haematology, 1980, 24, 87-94. | 0.0 | 15 |
| 98 | (D)-Penicillamine Treatment in Systemic Sclerosis (Scleroderma): Effect on Nutritional Capillary Circulation. Scandinavian Journal of Rheumatology, 1977, 6, 92-96. | 1.1 | 17 |
| 99 | IRON INTOXICATION IN TWO ADULT PATIENTS. Acta Medica Scandinavica, 1974, 196, 231-236. | 0.0 | 10 |